Hypervision Surgical raised £17 million (about $23 million) in a Series A financing for its surgical hyperspectral imaging platform. The company’s approach combines spectral sensing with cloud-enabled AI analytics to provide surgeons with real-time insights into tissue physiology during operations. The platform is designed to overcome what previously has been a visibility gap in tissue characterization, with potential implications for surgical navigation, margin assessment, and real-time decision support. Hypervision is also positioned to commercialize faster by building on AI-enabled signal processing and a cloud analysis layer. For investors, the round reflects continued funding appetite for med-tech systems that integrate sensing hardware with software to deliver measurable intraoperative utility.